Bushi Wang

Idarucizumab for Dabigatran Reversal

Charles V. Pollack, Paul A. Reilly, John W. Eikelboom et al. · New England Journal of Medicine · 2015 · 1.4K citations

Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

Charles V. Pollack, Paul Reilly, Joanne van Ryn et al. · New England Journal of Medicine · 2017 · 1.1K citations · Full text

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Jean‐Charles Soria, Enriqueta Felip, Manuel Cobo et al. · The Lancet Oncology · 2015 · 429 citations

Second-line Treatment, Afatinib Versus Erlotinib, Medicine +7

Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant <i>EGFR</i> -Mutant Lung Cancer with and without T790M Mutations

Yelena Y. Janjigian, Egbert F. Smit, Harry J.M. Groen et al. · Cancer Discovery · 2014 · 354 citations · Full text

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Paul A. Reilly, Richard A. Bernstein, Robert Dubiel et al. · Thrombosis and Haemostasis · 2015 · 153 citations